[go: up one dir, main page]

CO5590905A2 - Composiciones farmaceuticas que comprenden compuestos activos de vitamina d - Google Patents

Composiciones farmaceuticas que comprenden compuestos activos de vitamina d

Info

Publication number
CO5590905A2
CO5590905A2 CO04061816A CO04061816A CO5590905A2 CO 5590905 A2 CO5590905 A2 CO 5590905A2 CO 04061816 A CO04061816 A CO 04061816A CO 04061816 A CO04061816 A CO 04061816A CO 5590905 A2 CO5590905 A2 CO 5590905A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
composition according
phase component
emulsion
water
Prior art date
Application number
CO04061816A
Other languages
English (en)
Inventor
Andrew-Xian Chen
Fan Jan
Xi-Yun Yu
Martha J Whitehouse
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Publication of CO5590905A2 publication Critical patent/CO5590905A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Una composición farmacéutica que comprende: (a) un componente en fase lipofílica, (b) uno o más tensoactivos, y (c) un compuesto activo de vitamina D;en donde la composición es una emulsión preconcentrada, la cual, al ser diluida con agua en una relación de agua con respecto a la composición de aproximadamente 1: 1 ó más de agua, forma una emulsión que tiene una absorbancia mayor de 0.3 a 400 nanómetros. 2.- La composición farmacéutica de conformidad con la reivindicación 1, en donde la emulsión que se forma al diluir la emulsión preconcentrada con agua, es una emulsión con glóbulos de tamaño submicrónico.3.- La composición farmacéutica de conformidad con la reivindicación 1, en donde además comprende un componente de fase hidrofílica.4.- La composición farmacéutica de conformidad con la reivindicación 3, en donde el componente de fase hidrofílica comprende 1,2-propilenglicol.5.- La composición farmacéutica de conformidad con la reivindicación 4, en donde el componente de fase hidrofílica además comprende un alcanol de 1 a 5 átomos de carbono.6.- La composición farmacéutica de conformidad con la reivindicación 5, en donde el alcanol de 1 a 5 átomos de carbono es etanol.7.- La composición farmacéutica de conformidad con la reivindicación 1, en donde el componente de fase lipofílica comprende un monoglicérido, diglicérido o triglicérido.8.- La composición farmacéutica de conformidad con la reivindicación 7, en donde el componente de fase lipofílica comprende un triglicérido.9.- La composición farmacéutica de conformidad con la reivindicación 8, en donde el triglicérido se selecciona del grupo que consiste de aceites vegetales, aceites de pescado, grasas animales, aceites vegetales hidrogenados, aceites vegetales parcialmente hidrogenados, triglicéridos sintéticos, triglicéridos modificados, triglicéridos fraccionados y mezclas de los mismos.
CO04061816A 2001-12-03 2004-06-29 Composiciones farmaceuticas que comprenden compuestos activos de vitamina d CO5590905A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33455401P 2001-12-03 2001-12-03

Publications (1)

Publication Number Publication Date
CO5590905A2 true CO5590905A2 (es) 2005-12-30

Family

ID=23307754

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04061816A CO5590905A2 (es) 2001-12-03 2004-06-29 Composiciones farmaceuticas que comprenden compuestos activos de vitamina d

Country Status (17)

Country Link
US (2) US20030191093A1 (es)
EP (1) EP1461044A4 (es)
JP (1) JP2005515996A (es)
KR (1) KR20050044655A (es)
CN (1) CN100391464C (es)
AU (1) AU2002363959B2 (es)
BR (1) BR0214679A (es)
CA (1) CA2469119A1 (es)
CO (1) CO5590905A2 (es)
EA (1) EA008072B1 (es)
HU (1) HUP0501186A2 (es)
IL (1) IL162213A0 (es)
MX (1) MXPA04005260A (es)
NO (1) NO20042807L (es)
NZ (1) NZ533695A (es)
WO (1) WO2003047595A1 (es)
ZA (1) ZA200404735B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120682A2 (en) * 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンd化合物を含む薬学的組成物
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
CN100386083C (zh) * 2002-11-06 2008-05-07 诺瓦西股份有限公司 用维生素d类化合物制备治疗骨髓发育不良综合症药物的方法
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
ZA200510025B (en) * 2003-06-11 2007-03-28 Novacea Inc Pharmaceutical compositions comprising active vitamin D compounds
WO2005016872A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
WO2004110151A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
AU2004247108A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
CH698144B1 (fr) * 2003-09-24 2009-05-29 Bioxell Spa Analogue de la vitamine D3
US7332482B2 (en) 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
US20070129340A1 (en) * 2004-02-06 2007-06-07 Chugai Seiyaku Kabushiki Kaisha Ed-71 preparation
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
US20070275934A1 (en) * 2004-05-10 2007-11-29 Curd John G Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
CA2566346A1 (en) * 2004-05-10 2005-11-24 Novacea, Inc. Prevention of arterial restenosis with active vitamin d compounds
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
MX2007013029A (es) * 2005-04-22 2008-01-11 Novacea Inc Tratamiento, prevencion y mejora de trastornos pulmonares asociados con la quimioterapia o radioterapia con compuestos activos de vitamina d o substancias mimeticas de los mismos.
JP5140586B2 (ja) 2005-07-29 2013-02-06 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 滅菌パンクレアチン粉末の製法
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
FR2892936A1 (fr) * 2005-11-10 2007-05-11 Galderma Res & Dev Composition pharmaceutique ou cosmetique, et procede de solubilisation mixte pour preparer la composition.
EP1993559B1 (en) 2006-02-03 2016-06-22 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
CA2558202A1 (en) * 2006-09-14 2006-11-23 Reinhold W. Vieth Vitamin d compositions and method of administration to infants
JP2010525080A (ja) 2007-04-25 2010-07-22 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
CA2684778C (en) 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
HRP20231142T3 (hr) * 2007-04-25 2024-01-05 Eirgen Pharma Ltd. Kontrolirano oslobađanje 25-hidroksivitamina d
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
WO2009117152A1 (en) * 2008-03-20 2009-09-24 Virun, Inc. Emulsions including a peg-derivative of tocopherol
ES2954932T3 (es) 2008-04-02 2023-11-27 Eirgen Pharma Ltd Métodos, composiciones, usos y kits útiles para la deficiencia de vitamina D y trastornos relacionados
CN102770121B (zh) * 2009-12-22 2014-10-15 利奥制药有限公司 包含溶剂混合物和维生素d衍生物或类似物的药物组合物
CA2792330C (en) * 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
DK2680826T3 (en) 2011-03-02 2017-10-09 D3 Pharma Ltd VITAMIN D COMPOSITION
EP2811847B1 (en) 2012-02-10 2017-12-13 Virun, Inc. Beverage compositions containing non-polar compounds
EP2819998B1 (en) * 2012-03-01 2022-04-06 Array BioPharma Inc. Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1h-indazol-5-yloxy)benzyl)urea hydrochloride
CN102648917A (zh) * 2012-04-25 2012-08-29 杨烨 维生素d3在制备治疗多发性骨髓瘤药物中的应用
US9849088B2 (en) 2012-05-10 2017-12-26 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
CN103784419B (zh) * 2012-10-31 2016-03-30 成都国弘医药有限公司 一种含有骨化三醇的软胶囊及其制备方法
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules
WO2017115316A1 (en) 2015-12-29 2017-07-06 Noivita S.R.L.S. Lipophilic formulations
WO2017118885A1 (en) * 2016-01-04 2017-07-13 Gland Pharma Limited Stable pharmacuetical compositions of calcitriol
CN108883120A (zh) 2016-03-28 2018-11-23 欧普科爱尔兰环球控股有限公司 维生素d治疗方法
IL262565B (en) * 2016-06-06 2022-08-01 Celgene Corp Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CN109289041B (zh) * 2018-11-22 2021-11-26 福州大学 一种维生素d-胰岛素纳米缓释经皮制剂及其制备方法

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670190A (en) * 1973-01-10 1987-06-02 Hesse Robert H 1-α-hydroxy vitamin D compounds and process for preparing same
US3932634A (en) * 1973-06-28 1976-01-13 Pfizer Inc. High potency vitamin water dispersible formulations
DE2526938C2 (de) * 1975-02-14 1982-04-22 F. Hoffmann-La Roche & Co. AG, 4002 Basel Vitaminpräparate
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
JPS58210010A (ja) * 1982-05-31 1983-12-07 Kureha Chem Ind Co Ltd 抗腫瘍剤
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPH07100685B2 (ja) * 1985-08-02 1995-11-01 レオ・ファ−マシュ−ティカル・プロダクツ・リミテッド・エイ/エス(レ−ベンス・ケミスケ・ファブリック・プロデュクチオンスアクチ−セルスカブ) 新規ビタミンd類似体
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
JPS62149619A (ja) * 1985-09-05 1987-07-03 Teijin Ltd 活性型ビタミンd3類注射用組成物
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
US4784845A (en) * 1985-09-16 1988-11-15 American Cyanamid Company Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5229422A (en) * 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5182274A (en) * 1988-09-26 1993-01-26 Teijin Limited Stabilized aqueous preparation of active form of vitamin d3
JP2525478B2 (ja) * 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンd▲下3▼類固型製剤
US5085864A (en) * 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
US5260290A (en) * 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
JP3201411B2 (ja) * 1990-06-15 2001-08-20 メルシャン株式会社 ビタミンd類の生物学的製造方法
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
US5763428A (en) * 1990-09-21 1998-06-09 Bone Care International, Inc. Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US6538037B2 (en) * 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US5298246A (en) * 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
NZ242271A (en) * 1991-04-09 1993-10-26 Takeda Chemical Industries Ltd Medicaments containing a vitamin d compound stabilised by a basic substance
US5502224A (en) * 1991-06-04 1996-03-26 Marigen, S.A. Biotenside esters and phosphatides with vitamin-D and vitamin-E compounds
US5486509A (en) * 1991-06-28 1996-01-23 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
DK0600079T3 (da) * 1992-06-22 2002-04-15 Bone Care Int Inc Oral 1alpha-hydroxyprævitamin D
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
CA2096105A1 (en) * 1992-10-07 1994-04-08 Enrico Giuseppe Baggiolini (Deceased) Vitamin d3 fluorinated analogs
US5350745A (en) * 1993-01-29 1994-09-27 Lunar Corporation Treatment of myocardial failure
WO1995006482A1 (en) * 1993-09-01 1995-03-09 Teijin Limited 1α,24-(OH)2-VITAMIN D3 EMULSION COMPOSITION
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
AU696855B2 (en) * 1994-03-18 1998-09-17 Shire Laboratories, Inc. Emulsified drug delivery systems
CA2122431C (en) * 1994-04-28 2006-10-10 Reinhold W. Vieth Topical administration of vitamin d to mammals and compositions therefor
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5597575A (en) * 1994-06-06 1997-01-28 Breitbarth; Richard Composition for stimulating and inducing hair growth
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
DE69606680T2 (de) * 1995-10-30 2000-08-17 F. Hoffmann-La Roche Ag, Basel 1-Alpha, 26-dihydroxy-D-homo-vitamin D3
US6730679B1 (en) * 1996-03-22 2004-05-04 Smithkline Beecham Corporation Pharmaceutical formulations
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6034074A (en) * 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6573256B2 (en) * 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
PL336231A1 (en) * 1997-02-13 2000-06-19 Bone Care International System for aimed therapeutic delivery of vitamin d compounds
EP0979647A4 (en) * 1997-02-27 2006-07-19 Nippon Shinyaku Co Ltd FAT EMULSION FOR ORAL ADMINISTRATION
US6426078B1 (en) * 1997-03-17 2002-07-30 Roche Vitamins Inc. Oil in water microemulsion
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6599513B2 (en) * 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
AU728695B2 (en) * 1997-07-29 2001-01-18 Boehringer Ingelheim International Gmbh Self-emulsifying formulation for lipophilic compounds
US20030044434A1 (en) * 1997-07-29 2003-03-06 Ping Gao Self-emulsifying formulation for lipophilic compounds
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US5919986A (en) * 1997-10-17 1999-07-06 Hoffmann-La Roche Inc. D-homo vitamin D3 derivatives
EP2340840B1 (en) * 1998-03-27 2012-08-29 Oregon Health Sciences University Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases
US6277061B1 (en) * 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US20010002396A1 (en) * 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
US6552009B2 (en) * 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
AU5486899A (en) * 1998-08-13 2000-03-06 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
US6218430B1 (en) * 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
WO2000024712A1 (en) * 1998-10-23 2000-05-04 Teijin Limited Vitamin d3 derivatives and remedies for inflammatory respiratory diseases containing the same
FR2785284B1 (fr) * 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6524594B1 (en) * 1999-06-23 2003-02-25 Johnson & Johnson Consumer Companies, Inc. Foaming oil gel compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
PT1202957E (pt) * 1999-07-16 2005-01-31 Leo Pharma As Aminobenzofenonas como inibidoras de il-1beta e tnf-alpha
US6051567A (en) * 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en) * 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6211169B1 (en) * 1999-09-29 2001-04-03 Aesgen, Inc. Stable calcitriol solution for packaging into vials
AU7995300A (en) * 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
EP1239835B1 (en) * 1999-12-23 2013-03-20 Bend Research, Inc. Pharmaceutical compositions providing enhanced drug concentrations
AU2001260185A1 (en) * 2000-03-24 2001-10-03 Aventis Animal Nutrition S.A. Liquid vitamin composition
IL153378A0 (en) * 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンd化合物を含む薬学的組成物
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2005016872A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
WO2004110151A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
AU2004247108A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20070275934A1 (en) * 2004-05-10 2007-11-29 Curd John G Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
CA2566346A1 (en) * 2004-05-10 2005-11-24 Novacea, Inc. Prevention of arterial restenosis with active vitamin d compounds
WO2006074226A2 (en) * 2005-01-05 2006-07-13 Novacea, Inc. Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
MX2007013029A (es) * 2005-04-22 2008-01-11 Novacea Inc Tratamiento, prevencion y mejora de trastornos pulmonares asociados con la quimioterapia o radioterapia con compuestos activos de vitamina d o substancias mimeticas de los mismos.
AU2006294819A1 (en) * 2005-09-26 2007-04-05 Novacea, Inc. Prevention and treatment of gastrointestinal and bladder disorders using active vitamin D compounds

Also Published As

Publication number Publication date
CA2469119A1 (en) 2003-06-12
IL162213A0 (en) 2005-11-20
AU2002363959A1 (en) 2003-06-17
JP2005515996A (ja) 2005-06-02
CN1646136A (zh) 2005-07-27
MXPA04005260A (es) 2005-03-23
HUP0501186A2 (en) 2006-05-29
ZA200404735B (en) 2005-06-15
EA200400765A1 (ru) 2004-12-30
EP1461044A1 (en) 2004-09-29
NO20042807L (no) 2004-07-02
EP1461044A4 (en) 2007-06-13
KR20050044655A (ko) 2005-05-12
US20030191093A1 (en) 2003-10-09
BR0214679A (pt) 2004-12-14
AU2002363959B2 (en) 2007-12-13
EA008072B1 (ru) 2007-02-27
WO2003047595A1 (en) 2003-06-12
US20070003614A1 (en) 2007-01-04
CN100391464C (zh) 2008-06-04
NZ533695A (en) 2007-04-27

Similar Documents

Publication Publication Date Title
CO5590905A2 (es) Composiciones farmaceuticas que comprenden compuestos activos de vitamina d
US8937194B2 (en) Topical compositions containing nitro fatty acids
NO20000467L (no) Farmasøytisk preparat i form av en selvemulgerende formulering for lipofile forbindelser
RU2018133932A (ru) Фармацевтическая композиция стероидного гормона
AR040205A1 (es) Composicion herbicida
AR065861A1 (es) Formulaciones farmaceuticas basadas en lipidos apolares y polares para uso oftalmico
DK1504081T3 (da) Håndrensende formulering
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
US20160058780A1 (en) Composition for lipolysis, containing phosphatidylcholine, and preparation method therefor
JP2002541086A5 (es)
CO5570649A2 (es) Producto antitranspirante en gel liquido de alta eficiencia
RU2010121989A (ru) Композиция для местного введения
AR052252A1 (es) Formulaciones topicas de nepafenac
BRPI0411306A (pt) composições farmacêuticas compreendendo compostos ativos de vitamina d
AR056808A1 (es) Formulacion de aceite en agua de avermectinas
AR045094A1 (es) Formulaciones liofilizadas de cci-779
AR043106A2 (es) Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica
RU2010103038A (ru) Композиции для персонального ухода, обладающие ослабленным раздражающим действием на глаза
CO6321129A2 (es) Inhibidor de la cristalizacion y su uso en capsulas de gelatina
RU2015102597A (ru) Липидные композиции рацекадотрила
ES2154806T3 (es) Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles.
SE0000774D0 (sv) New formulation
CO5611133A2 (es) Composicion oftalmica que comprende ascomicina
AR040859A1 (es) Composiciones farmaceuticas que comprenden una ascomicina
DE50212331D1 (de) O/w-emulsionen mit unpolaren wirkstoffen

Legal Events

Date Code Title Description
FC Application refused